| Autor: |
Mangaiarkarasi S. Asokan, Roshni Florina Joan, Sudhir Babji, Girish Dayma, Prajitha Nadukkandy, Vinutha Subrahmanyam, Archana Pandey, Girish Malagi, Pooja Arya, Vibhuti Mahajan, Jayateerth Bhavikatti, Ketakee Pawar, Aishwarya Thorat, Priyanki Shah, Ramakrishna B. Goud, Bishnudeo Roy, Shon Rajukutty, Sushil Immanuel, Dhiraj Agarwal, Sankhanil Saha, Akshatha Shivaraj, Patricia Panikulam, Rajeshwari Shome, Shah-E-Jahan Gulzar, Anusmrithi U. Sharma, Ajinkya Naik, Shruti Talashi, Madhuri Belekar, Ritu Yadav, Poornima Khude, Mamatha V, Sudarshan Shivalingaiah, Urmila Deshmukh, Chinmayee Bhise, Manjiri Joshi, Leeberk Raja Inbaraj, Sindhulina Chandrasingh, Aurnab Ghose, Colin Jamora, Anandi S. Karumbati, Varadharajan Sundaramurthy, Avita Johnson, Naveen Ramesh, Nirutha Chetan, Chaitra Parthiban, Asma Ahmed, Srabanti Rakshit, Vasista Adiga, George D'souza, Vinay Rale, Carolin Elizabeth George, Jacob John, Anand Kawade, Akanksha Chaturvedi, Anu Raghunathan, Mary Dias, Anand Bhosale, Padinjat Raghu, L.S. Shashidhara, Annapurna Vyakarnam, Vineeta Bal, Gagandeep Kang, Satyajit Mayor |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
The Lancet Regional Health - Southeast Asia, Vol 22, Iss , Pp 100361- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2772-3682 |
| DOI: |
10.1016/j.lansea.2024.100361 |
| Popis: |
Summary: Background: There are limited global data on head-to-head comparisons of vaccine platforms assessing both humoral and cellular immune responses, stratified by pre-vaccination serostatus. The COVID-19 vaccination drive for the Indian population in the age group 18–45 years began in April 2021 when seropositivity rates in the general population were rising due to the delta wave of COVID-19 pandemic during April–May 2021. Methods: Between June 30, 2021, and Jan 28, 2022, we enrolled 691 participants in the age group 18–45 years across four clinical sites in India. In this non-randomised and laboratory blinded study, participants received either two doses of Covaxin® (4 weeks apart) or two doses of Covishield™ (12 weeks apart) as per the national vaccination policy. The primary outcome was the seroconversion rate and the geometric mean titre (GMT) of antibodies against the SARS-CoV-2 spike and nucleocapsid proteins post two doses. The secondary outcome was the frequency of cellular immune responses pre- and post-vaccination. Findings: When compared to pre-vaccination baseline, both vaccines elicited statistically significant seroconversion and binding antibody levels in both seronegative and seropositive individuals. In the per-protocol cohort, Covishield™ elicited higher antibody responses than Covaxin® as measured by seroconversion rate (98.3% vs 74.4%, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
